Top

Published in:

Open Access 01-12-2013 | Review

Cytokine-induced killer cells promote antitumor immunity

Authors: Jingting Jiang, Changping Wu, Binfeng Lu

Published in: Journal of Translational Medicine | Issue 1/2013

Abstract

The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly Th1 cells, CD8 T cells, and NK cells is associated with increased survival of cancer patients. Such antitumor cellular immune responses can be greatly enhanced by adoptive transfer of activated type 1 lymphocytes. Recently, adoptive cell therapy based on infusion of ex vivo expanded TILs has achieved substantial clinical success. Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8 T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Preclinical studies of CIK cells in murine tumor models demonstrate significant antitumor effects against a number of hematopoietic and solid tumors. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with comparable malignancies. Enhancing the potency and specificity of CIK therapy via immunological and genetic engineering approaches and identifying robust biomarkers of response will significantly improve this therapy.

Available only for authorised users

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N: Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011, 9: 214-10.1186/1479-5876-9-214.PubMedCentralCrossRefPubMed

Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G: Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011, 71: 5601-5605. 10.1158/0008-5472.CAN-11-1316.CrossRefPubMed

Mitchison NA: Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med. 1955, 102: 157-177. 10.1084/jem.102.2.157.PubMedCentralCrossRefPubMed

Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011, 17: 4550-4557. 10.1158/1078-0432.CCR-11-0116.PubMedCentralCrossRefPubMed

Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986, 233: 1318-1321. 10.1126/science.3489291.CrossRefPubMed

Yron I, Wood TA, Spiess PJ, Rosenberg SA: In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 1980, 125: 238-245.PubMed

Lotze MT, Line BR, Mathisen DJ, Rosenberg SA: The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980, 125: 1487-1493.PubMed

Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984, 225: 1487-1489. 10.1126/science.6332379.CrossRefPubMed

Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011, 17: 6287-6297. 10.1158/1078-0432.CCR-11-1347.PubMedCentralCrossRefPubMed

10.

Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981, 41: 4420-4425.PubMed

11.

Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH: Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol. 1987, 138: 2728-2733.PubMed

12.

Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991, 174: 139-149. 10.1084/jem.174.1.139.CrossRefPubMed

13.

Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993, 21: 1673-1679.PubMed

14.

Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005, 11: 181-187. 10.1016/j.bbmt.2004.11.019.CrossRefPubMed

15.

Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L: Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol. 2008, 20: 841-848. 10.1093/intimm/dxn042.CrossRefPubMed

16.

Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994, 153: 1687-1696.PubMed

17.

Silva MR, Parreira A, Ascensao JL: Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. Exp Hematol. 1995, 23: 1676-1681.PubMed

18.

Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS: Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998, 92: 3318-3327.PubMed

19.

Linn YC, Lau LC, Hui KM: Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002, 116: 78-86. 10.1046/j.1365-2141.2002.03247.x.CrossRefPubMed

20.

Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S: Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol. 2003, 77: 175-179. 10.1007/BF02983217.CrossRefPubMed

21.

Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY, Chen JM: Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol. 2002, 8: 464-468.PubMed

22.

Sun S, Li XM, Li XD, Yang WS: Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm. 2005, 20: 173-180. 10.1089/cbr.2005.20.173.CrossRefPubMed

23.

Kim HM, Lim J, Park SK, Kang JS, Lee K, Lee CW, Lee KH, Yun MJ, Yang KH, Han G: Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol. 2007, 7: 1802-1807. 10.1016/j.intimp.2007.08.016.CrossRefPubMed

24.

Wang P, Yu JP, Gao SY, An XM, Ren XB, Wang XG, Li WL: Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells. Cell Immunol. 2008, 253: 59-65. 10.1016/j.cellimm.2008.04.014.CrossRefPubMed

25.

Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA: Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001, 7: 532-542. 10.1016/S1083-8791(01)70014-6.CrossRefPubMed

26.

Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS: Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood. 1995, 86: 3493-3499.PubMed

27.

Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M: Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 2011, 118: 3301-3310. 10.1182/blood-2011-02-336321.CrossRefPubMed

28.

Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC: Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001, 294: 605-609. 10.1126/science.1063916.CrossRefPubMed

29.

Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS: Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 2005, 175: 7819-7828.CrossRefPubMed

30.

Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IG: Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk Res. 2011, 35: 1136-1142. 10.1016/j.leukres.2011.05.005.CrossRefPubMed

31.

Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS: Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001, 97: 2923-2931. 10.1182/blood.V97.10.2923.CrossRefPubMed

32.

Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS: Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003, 101: 640-648. 10.1182/blood-2002-06-1751.CrossRefPubMed

33.

Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999, 81: 1009-1016. 10.1038/sj.bjc.6690800.PubMedCentralCrossRefPubMed

34.

Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P: Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006, 26: 2237-2242.PubMed

35.

Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D’Amico G, Biagi E: Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007, 92: 952-959. 10.3324/haematol.11132.CrossRefPubMed

36.

Wu C, Jiang J, Shi L, Xu N: Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008, 28: 3997-4002.PubMed

37.

Hui D, Qiang L, Jian W, Ti Z, Da-Lu K: A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009, 41: 36-41. 10.1016/j.dld.2008.04.007.CrossRefPubMed

38.

Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A: Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009, 27: 130-139. 10.1002/hon.886.CrossRefPubMed

39.

Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, Zheng X, Sun J, Lu BF, Zhang XG: Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol. 2010, 16: 6155-6162. 10.3748/wjg.v16.i48.6155.PubMedCentralCrossRefPubMed

40.

Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S: Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011, 17: 1679-1687. 10.1016/j.bbmt.2011.05.012.PubMedCentralCrossRefPubMed

41.

Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X: Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012, 18: 1751-1759. 10.1158/1078-0432.CCR-11-2442.CrossRefPubMed

42.

Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011, 137: 305-310. 10.1007/s00432-010-0887-7.CrossRefPubMed

43.

Li X, Xu B, Wu J: Review of Chinese clinical trial trials on CIK cell treatment for malignancies. Clin Transl Oncol. 2012, 14: 242-245.CrossRef

44.

Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt-Wolf IG: Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine. 2000, 12: 1385-1390. 10.1006/cyto.2000.0733.CrossRefPubMed

45.

Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, Huang K, Zhou DH: Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res. 2010, 30: 3493-3499.PubMed

46.

Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M: The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy. 2011, 6: 6-

47.

Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, Micka B, Roigk K, Fehlinger M, Schmidt-Wolf GD: Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or −12. Cancer Immunol Immunother. 1998, 47: 221-226. 10.1007/s002620050524.CrossRefPubMed

48.

Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH: IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother. 2010, 59: 1325-1334. 10.1007/s00262-010-0860-y.CrossRefPubMed

49.

Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995, 378: 88-91. 10.1038/378088a0.CrossRefPubMed

50.

Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, Zhang X, Finn OJ, Chen X, Lu B: IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol. 2011, 41: 3351-3360. 10.1002/eji.201141629.PubMedCentralCrossRefPubMed

51.

Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC, Osband ME: Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur J Cancer. 1995, 31A: 698-708.CrossRefPubMed

52.

Galluzzi L, Senovilla L, Zitvogel L, Kroemer G: The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012, 11: 215-233. 10.1038/nrd3626.CrossRefPubMed

53.

Butterfield LH, Vujanovic L: New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Curr Opin Investig Drugs. 2010, 11: 1399-1408.PubMedCentralPubMed

54.

Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G: Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011, 334: 1573-1577. 10.1126/science.1208347.CrossRefPubMed

55.

Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM: New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med. 2012, 10: 48-10.1186/1479-5876-10-48.PubMedCentralCrossRefPubMed

56.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006, 314: 126-129. 10.1126/science.1129003.PubMedCentralCrossRefPubMed

57.

Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009, 114: 535-546. 10.1182/blood-2009-03-211714.PubMedCentralCrossRefPubMed

58.

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011, 29: 917-924. 10.1200/JCO.2010.32.2537.PubMedCentralCrossRefPubMed

59.

Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010, 116: 4099-4102. 10.1182/blood-2010-04-281931.PubMedCentralCrossRefPubMed

60.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011, 3: 95ra73-10.1126/scitranslmed.3002842.PubMedCentralCrossRefPubMed

61.

Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011, 118: 4817-4828. 10.1182/blood-2011-04-348540.PubMedCentralCrossRefPubMed

62.

Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2011, 8: 8-

63.

Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH: Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res. 2006, 12: 1859-1867. 10.1158/1078-0432.CCR-05-2019.CrossRefPubMed

64.

Thakur A, Lum LG: Cancer therapy with bispecific antibodies: clinical experience. Curr Opin Mol Ther. 2010, 12: 340-349.PubMedCentralPubMed

65.

Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH: Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther. 2011, 11: 843-853. 10.1517/14712598.2011.572874.CrossRefPubMed

66.

Dugast AS, Haudebourg T, Coulon F, Heslan M, Haspot F, Poirier N, Vuillefroy de Silly R, Usal C, Smit H, Martinet B: Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol. 2008, 180: 7898-7906.CrossRefPubMed

67.

Haymaker C, Wu R, Bernatchez C, Radvanyi L: PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint. Oncoimmunology. 2012, 1: 735-738. 10.4161/onci.20823.PubMedCentralCrossRefPubMed

68.

Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F: Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. J Immunother. 2012, 35: 579-586. 10.1097/CJI.0b013e31826b1fd9.CrossRefPubMed

69.

Thorne SH, Negrin RS, Contag CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006, 311: 1780-1784. 10.1126/science.1121411.CrossRefPubMed

70.

Tang D, Kang R, Livesey KM, Zeh HJ, Lotze MT: High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal. 2011, 15: 2185-2195. 10.1089/ars.2010.3666.PubMedCentralCrossRefPubMed

71.

Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E: Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011, 17: 654-666. 10.1158/1078-0432.CCR-10-2634.PubMedCentralCrossRefPubMed

72.

Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, Lotze MT: Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010, 190: 881-892. 10.1083/jcb.200911078.PubMedCentralCrossRefPubMed

73.

Rettinger E, Meyer V, Kreyenberg H, Volk A, Kuci S, Willasch A, Koscielniak E, Fulda S, Wels WS, Boenig H: Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front Oncol. 2012, 2: 32-PubMedCentralCrossRefPubMed

74.

Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M: CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res. 2012, 18: 5352-5363. 10.1158/1078-0432.CCR-12-0628.PubMedCentralCrossRefPubMed

75.

Sabbagh L, Kaech SM, Bourbonniere M, Woo M, Cohen LY, Haddad EK, Labrecque N, Ahmed R, Sekaly RP: The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol. 2004, 173: 5425-5433.CrossRefPubMed

76.

Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, Gapin L, Kaech SM: Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007, 27: 281-295. 10.1016/j.immuni.2007.07.010.PubMedCentralCrossRefPubMed

77.

Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E: Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest. 2013, 123 (2): 594-599.PubMedCentralPubMed

78.

Lu B: The molecular mechanisms that control function and death of effector CD4+ T cells. Immunol Res. 2006, 36: 275-282. 10.1385/IR:36:1:275.CrossRefPubMed

79.

Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005, 65: 1089-1096.PubMed

80.

Kobori H, Hashiguchi M, Piao J, Kato M, Ritprajak P, Azuma M: Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites. Immunology. 2010, 130: 363-373. 10.1111/j.1365-2567.2009.03236.x.PubMedCentralCrossRefPubMed

Title: Cytokine-induced killer cells promote antitumor immunity
Authors: Jingting Jiang
Changping Wu
Binfeng Lu
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-11-83

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cytokine-induced killer cells promote antitumor immunity

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Long non-coding RNA expression profile in human gastric cancer and its clinical significances

Betaine supplement enhances skeletal muscle differentiation in murine myoblasts via IGF-1 signaling activation

Increased long-term expression of pentraxin 3 in irradiated human arteries and veins compared to internal controls from free tissue transfers

Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs – an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research

Detection of colon polyps by a novel, polymer pattern-based full blood test

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page